DK1729734T3 - Spröjtetörrede farmaceutiske præparater - Google Patents

Spröjtetörrede farmaceutiske præparater

Info

Publication number
DK1729734T3
DK1729734T3 DK05730200T DK05730200T DK1729734T3 DK 1729734 T3 DK1729734 T3 DK 1729734T3 DK 05730200 T DK05730200 T DK 05730200T DK 05730200 T DK05730200 T DK 05730200T DK 1729734 T3 DK1729734 T3 DK 1729734T3
Authority
DK
Denmark
Prior art keywords
spray
pharmaceutical preparations
dried pharmaceutical
dried
preparations
Prior art date
Application number
DK05730200T
Other languages
Danish (da)
English (en)
Inventor
Vlasios Andronis
Rennan Pan
Kamlesh Rameshchandra Patel
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK1729734T3 publication Critical patent/DK1729734T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05730200T 2004-03-30 2005-03-28 Spröjtetörrede farmaceutiske præparater DK1729734T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55757104P 2004-03-30 2004-03-30
PCT/US2005/010350 WO2005097077A2 (en) 2004-03-30 2005-03-28 Spray dried pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DK1729734T3 true DK1729734T3 (da) 2008-06-16

Family

ID=34956393

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05730200T DK1729734T3 (da) 2004-03-30 2005-03-28 Spröjtetörrede farmaceutiske præparater

Country Status (27)

Country Link
US (1) US20070178151A1 (es)
EP (1) EP1729734B1 (es)
JP (1) JP2007530702A (es)
KR (1) KR20060135000A (es)
CN (1) CN1933816A (es)
AR (1) AR048193A1 (es)
AT (1) ATE387189T1 (es)
AU (1) AU2005231355B2 (es)
BR (1) BRPI0508111A (es)
CA (1) CA2556461A1 (es)
DE (1) DE602005005033T2 (es)
DK (1) DK1729734T3 (es)
ES (1) ES2301003T3 (es)
HK (1) HK1099213A1 (es)
HR (1) HRP20080154T3 (es)
IL (1) IL177606A0 (es)
IS (1) IS8548A (es)
MA (1) MA28557B1 (es)
NO (1) NO20064864L (es)
NZ (1) NZ549096A (es)
PE (1) PE20060161A1 (es)
PL (1) PL1729734T3 (es)
PT (1) PT1729734E (es)
RU (1) RU2006138054A (es)
TW (1) TW200602055A (es)
WO (1) WO2005097077A2 (es)
ZA (1) ZA200606670B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
TW200803854A (en) * 2005-09-30 2008-01-16 Smithkline Beecham Corp Pharmaceutical compositions
EP1940357A2 (en) * 2005-09-30 2008-07-09 SmithKline Beecham Corporation Pharmaceutical compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2227769T3 (es) * 1994-05-27 2005-04-01 Glaxosmithkline S.P.A. Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina.
US6936277B2 (en) * 1995-01-09 2005-08-30 J. Rettenmaier & Soehne Gmbh & Co. Kg Pharmaceutical excipient having improved compressibility
DE19501269A1 (de) * 1995-01-18 1996-07-25 Henkel Kgaa Amorphes Alkalisilikat-Compound
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
ATE367802T1 (de) * 2000-09-20 2007-08-15 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
MY134211A (en) * 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
ATE371442T1 (de) * 2001-10-12 2007-09-15 Elan Pharma Int Ltd Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung

Also Published As

Publication number Publication date
DE602005005033T2 (de) 2009-03-19
MA28557B1 (fr) 2007-04-03
WO2005097077A2 (en) 2005-10-20
EP1729734A2 (en) 2006-12-13
AU2005231355B2 (en) 2008-09-18
ES2301003T3 (es) 2008-06-16
AU2005231355A1 (en) 2005-10-20
IS8548A (is) 2006-10-06
CN1933816A (zh) 2007-03-21
NO20064864L (no) 2006-10-25
RU2006138054A (ru) 2008-05-10
ATE387189T1 (de) 2008-03-15
EP1729734B1 (en) 2008-02-27
NZ549096A (en) 2009-05-31
AR048193A1 (es) 2006-04-05
CA2556461A1 (en) 2005-10-20
BRPI0508111A (pt) 2007-07-17
DE602005005033D1 (de) 2008-04-10
WO2005097077A3 (en) 2006-04-13
HK1099213A1 (en) 2007-08-10
KR20060135000A (ko) 2006-12-28
ZA200606670B (en) 2008-01-30
TW200602055A (en) 2006-01-16
JP2007530702A (ja) 2007-11-01
US20070178151A1 (en) 2007-08-02
HRP20080154T3 (en) 2008-10-31
PL1729734T3 (pl) 2008-09-30
PT1729734E (pt) 2008-05-29
IL177606A0 (en) 2006-12-10
PE20060161A1 (es) 2006-05-10

Similar Documents

Publication Publication Date Title
MA28489B1 (fr) Preparations pharmaceutiques
NO20075628L (no) Farmasøytiske formuleringer
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0511900A (pt) composições farmacêuticas
DK1750683T3 (da) Formuleringer med langvarig frigivelse
FR2889449B1 (fr) Preparations implantables
DK1957073T3 (da) Lægemiddel
DK1959991T3 (da) Terapeutisk vaccine
DE602004017700D1 (de) Transmukosen verabreichung
MA28609B1 (fr) Vaccins
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
PT1501534E (pt) Formulacoes farmaceuticas
DK1941798T3 (da) Nematicide præparater
GB0426301D0 (en) Pharmaceutical formulations
MA28885B1 (fr) vaccins
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
DK1809660T3 (da) Thymus-specifikt protein
DK2918286T3 (da) En farmaceutisk formulering
DK1791872T3 (da) Biotinylerede hexadecasaccharider, farmaceutiske præparater og anvendelse heraf
GB0416397D0 (en) Pharmaceutical formulations
IS8548A (is) Úðaþurrkaðar lyfjablöndur
ATE546141T1 (de) Pharmazeutisches injektionspräparat
SE0601411L (sv) Förfarande vid beredning
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante